Suppr超能文献

粪便微生物移植后细菌菌株的精确定量可描绘长期定植情况并解释结果。

Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes.

机构信息

Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Nat Microbiol. 2021 Oct;6(10):1309-1318. doi: 10.1038/s41564-021-00966-0. Epub 2021 Sep 27.

Abstract

Fecal microbiota transplantation (FMT) has been successfully applied to treat recurrent Clostridium difficile infection in humans, but a precise method to measure which bacterial strains stably engraft in recipients and evaluate their association with clinical outcomes is lacking. We assembled a collection of >1,000 different bacterial strains that were cultured from the fecal samples of 22 FMT donors and recipients. Using our strain collection combined with metagenomic sequencing data from the same samples, we developed a statistical approach named Strainer for the detection and tracking of bacterial strains from metagenomic sequencing data. We applied Strainer to evaluate a cohort of 13 FMT longitudinal clinical interventions and detected stable engraftment of 71% of donor microbiota strains in recipients up to 5 years post-FMT. We found that 80% of recipient gut bacterial strains pre-FMT were eliminated by FMT and that post-FMT the strains present persisted up to 5 years later, together with environmentally acquired strains. Quantification of donor bacterial strain engraftment in recipients independently explained (precision 100%, recall 95%) the clinical outcomes (relapse or success) after initial and repeat FMT. We report a compendium of bacterial species and strains that consistently engraft in recipients over time that could be used in defined live biotherapeutic products as an alternative to FMT. Our analytical framework and Strainer can be applied to systematically evaluate either FMT or defined live bacterial therapeutic studies by quantification of strain engraftment in recipients.

摘要

粪便微生物群移植(FMT)已成功应用于治疗人类复发性艰难梭菌感染,但缺乏一种精确的方法来衡量哪些细菌菌株在受者中稳定定植,并评估其与临床结果的关联。我们收集了来自 22 名 FMT 供体和受者粪便样本的 >1000 种不同细菌菌株,并将其组合在一起。利用我们的菌株收集和来自相同样本的宏基因组测序数据,我们开发了一种名为 Strainer 的统计方法,用于从宏基因组测序数据中检测和跟踪细菌菌株。我们应用 Strainer 评估了 13 例 FMT 纵向临床干预的队列,并在 FMT 后长达 5 年内检测到 71%的供体微生物群菌株在受者中稳定定植。我们发现,80%的受者肠道细菌菌株在 FMT 前被消除,而 FMT 后存在的菌株可持续存在长达 5 年,同时还有环境获得的菌株。供体细菌菌株在受者中的定植程度的定量独立解释了(初始和重复 FMT 后的准确性为 100%,召回率为 95%)临床结果(复发或成功)。我们报告了一组随着时间的推移在受者中持续定植的细菌物种和菌株,这些菌株可以在定义的活体生物治疗产品中替代 FMT。我们的分析框架和 Strainer 可以通过定量受者中菌株的定植来系统地评估 FMT 或定义的活体细菌治疗研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0124/8993687/7ed792ff2e2d/41564_2021_966_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验